Skip to main content

dPCR Mutational Analyses in Cell-Free DNA: A Comparison with Tissues

  • Protocol
  • First Online:
Book cover Cell-free DNA as Diagnostic Markers

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1909))

Abstract

Digital PCR (dPCR) enables the detection and characterization of fragmented DNA that is in low abundance in blood. Here, we describe the comparative analysis of mutations in tumor tissue DNA and plasma cell-free DNA (cfDNA) using a dPCR method. Tumor cells are captured by laser microdissection to obtain only cancerous cells from a small quantity of metastatic tissue samples and to exclude inflammatory and stromal cells. We extracted cfDNA from 500 μL of plasma, which is sufficient for target mutation analysis using dPCR. The dPCR assay for the detection of the specific region in the target gene consists of a pair of primers and two probes labeled with a fluorescent dye capable to recognize the presence or absence of a specific mutation. Using the dPCR method, we can identify only a few mutations in tissue that are present also in plasma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Diaz LA Jr, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32:579–586

    Article  Google Scholar 

  2. Dawson SJ, Tsui DW, Murtaza M et al (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368:1199–1209

    Article  CAS  Google Scholar 

  3. Garcia-Murillas I, Schiavon G, Weigelt B et al (2015) Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 7:302ra133

    Article  Google Scholar 

  4. Diehl F, Schmidt K, Choti MA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985–990

    Article  CAS  Google Scholar 

  5. Hindson BJ, Ness KD, Masquelier DA et al (2011) High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 83:8604–8610

    Article  CAS  Google Scholar 

  6. Dressman D, Yan H, Traverso G et al (2003) Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A 100:8817–8822

    Article  CAS  Google Scholar 

  7. Vogelstein B, Kinzler KW, Digital PCR (1999) Proc Natl Acad Sci U S A 96:9236–9241

    Article  CAS  Google Scholar 

  8. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M et al (2015) Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. Transl Res 166:540–553, e542

    Article  CAS  Google Scholar 

  9. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M et al (2017) Comparison of ESR1 mutations in tumor tissue and matched plasma samples from metastatic breast cancer patients. Transl Oncol 10:766–771

    Article  Google Scholar 

  10. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M et al (2017) Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients. BMC Cancer 17:786

    Article  Google Scholar 

  11. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M et al (2017) Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients. Oncotarget 8:52142–52155

    Article  Google Scholar 

  12. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M et al (2018) Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer. Mol Cancer 17:67

    Article  Google Scholar 

  13. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M et al (2016) Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients. Oncotarget 7:32504–32518

    Article  Google Scholar 

Download references

Acknowledgments

This work was supported in part by a grant-in-aid (project number 17K16511) for scientific research from the Ministry of Education, Science and Culture of Japan. The authors wish to thank Dr. Qui Shi, M.D., and Ms. Ikuko Suzu for their excellent technical support.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hirotaka Iwase .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Takeshita, T., Iwase, H. (2019). dPCR Mutational Analyses in Cell-Free DNA: A Comparison with Tissues. In: Casadio, V., Salvi, S. (eds) Cell-free DNA as Diagnostic Markers. Methods in Molecular Biology, vol 1909. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8973-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-8973-7_8

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-8972-0

  • Online ISBN: 978-1-4939-8973-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics